|

CC-99282 Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: BMS-986369

Pipeline

Phase 1: 1Phase 2: 2

Top Sponsors

  • M.D. Anderson Cancer Center1
  • Genmab1
  • Celgene1

Indications

  • Cancer3
  • Lymphoma, B-Cell1
  • Tumor1
  • Non-hodgkin Lymphoma1
  • Follicular Lymphoma1

Scottsdale, Arizona1 trial

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Mayo Clinic - Arizona

Phase 1

Tucson, Arizona1 trial

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

The University of Arizona Cancer Center - North Campus /ID# 242219

Phase 2

Houston, Texas1 trial

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.